{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:40:47Z","timestamp":1761662447635},"reference-count":44,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Viral hepatitis is the third most common cause of liver disease in allogeneic transplant recipients and causes significant morbidity and mortality. When treating patients with hematological malignancies, an emphasis should be placed on identification of patients at risk for viral hepatitis with appropriate screening. Initial screening serology should include anti-HCV, HBsAg, anti-HBs, and anti-HBc testing. When hepatitis B exposure has been documented, prophylaxis of viral reactivation for all HBsAg-positive patients with a nucleoside analogue should be implemented. HCV infection appears to have little short-term impact on survival after bone marrow transplantation, but is a risk factor for veno-occlusive disease (VOD) and graft-versus-host disease (GVHD). In the long-term survivor, HCV infection can lead to significant morbidity and mortality due to the development of cirrhosis, decompensation, and liver cancer. Since effective antiviral therapies are available for both hepatitis B and C, routine screening and selected intervention is recommended once reactivation and disease recurrence is documented. In this chapter we will highlight the mechanisms of virus reactivation, clinical manifestations, and management strategies to minimize acute and chronic morbidity in this population.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.375","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"375-380","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Viral Hepatitis: Manifestations and Management Strategy"],"prefix":"10.1182","volume":"2006","author":[{"given":"Roberto J.","family":"Firpi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111704362880700_R1","doi-asserted-by":"crossref","unstructured":"Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733\u20131745.","DOI":"10.1056\/NEJM199712113372406"},{"key":"2019111704362880700_R2","unstructured":"Firpi RJ, Martin P. Update on hepatitis B treatment. MedGenMed. 2002;4:9."},{"key":"2019111704362880700_R3","doi-asserted-by":"crossref","unstructured":"Dai MS, Chao TY. Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive? Breast Cancer Res Treat. 2005;92:95\u201396.","DOI":"10.1007\/s10549-005-1942-y"},{"key":"2019111704362880700_R4","doi-asserted-by":"crossref","unstructured":"Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597\u20131603.","DOI":"10.1136\/gut.2005.070763"},{"key":"2019111704362880700_R5","doi-asserted-by":"crossref","unstructured":"Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol. 2001;67:45\u201350.","DOI":"10.1034\/j.1600-0609.2001.067001045.x"},{"key":"2019111704362880700_R6","doi-asserted-by":"crossref","unstructured":"Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320\u20131325.","DOI":"10.1002\/cncr.21701"},{"key":"2019111704362880700_R7","doi-asserted-by":"crossref","unstructured":"Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore\/core mutations may play an important role. J Med Virol. 2000;60:249\u2013255.","DOI":"10.1002\/(SICI)1096-9071(200003)60:3<249::AID-JMV1>3.0.CO;2-C"},{"key":"2019111704362880700_R8","doi-asserted-by":"crossref","unstructured":"Nagington J. Reactivation of hepatitis B after transplantation operations. Lancet. 1977;1:558\u2013560.","DOI":"10.1016\/S0140-6736(77)91995-X"},{"key":"2019111704362880700_R9","doi-asserted-by":"crossref","unstructured":"Nordbo SA, Skaug K, Holter E, Waage A, Brinch L. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol. 2000;65:86\u201387.","DOI":"10.1034\/j.1600-0609.2000.9l228.x"},{"key":"2019111704362880700_R10","doi-asserted-by":"crossref","unstructured":"Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105\u2013112.","DOI":"10.1016\/S0016-5085(75)80054-0"},{"key":"2019111704362880700_R11","doi-asserted-by":"crossref","unstructured":"Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17:394\u2013398.","DOI":"10.1200\/JCO.1999.17.1.394"},{"key":"2019111704362880700_R12","doi-asserted-by":"crossref","unstructured":"Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182\u2013188.","DOI":"10.1016\/0016-5085(91)90599-G"},{"key":"2019111704362880700_R13","doi-asserted-by":"crossref","unstructured":"Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299\u2013307.","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0"},{"key":"2019111704362880700_R14","doi-asserted-by":"crossref","unstructured":"Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209\u2013220.","DOI":"10.1002\/hep.21051"},{"key":"2019111704362880700_R15","doi-asserted-by":"crossref","unstructured":"Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55\u201359.","DOI":"10.1046\/j.1352-0504.2003.00467.x"},{"key":"2019111704362880700_R16","doi-asserted-by":"crossref","unstructured":"Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy\u2014pathogenesis and management. Rev Med Virol. 2001;11:287\u2013299.","DOI":"10.1002\/rmv.322"},{"key":"2019111704362880700_R17","doi-asserted-by":"crossref","unstructured":"Knoll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925\u2013929.","DOI":"10.1038\/sj.bmt.1704457"},{"key":"2019111704362880700_R18","doi-asserted-by":"crossref","unstructured":"McIvor C, Morton J, Bryant A, Cooksley WG, Durrant S, Walker N. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med. 1994;121:274\u2013275.","DOI":"10.7326\/0003-4819-121-4-199408150-00007"},{"key":"2019111704362880700_R19","doi-asserted-by":"crossref","unstructured":"Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37:1320\u20131328.","DOI":"10.1053\/jhep.2003.50220"},{"key":"2019111704362880700_R20","doi-asserted-by":"crossref","unstructured":"Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270\u2013275.","DOI":"10.1007\/s00277-003-0825-8"},{"key":"2019111704362880700_R21","doi-asserted-by":"crossref","unstructured":"Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927\u2013934.","DOI":"10.1200\/JCO.2004.05.161"},{"key":"2019111704362880700_R22","doi-asserted-by":"crossref","unstructured":"Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742\u20131749.","DOI":"10.1053\/j.gastro.2003.09.026"},{"key":"2019111704362880700_R23","doi-asserted-by":"crossref","unstructured":"Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88:209\u2013215.","DOI":"10.1007\/s10549-004-0725-1"},{"key":"2019111704362880700_R24","doi-asserted-by":"crossref","unstructured":"Hui CK, Lie A, Au WY, et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant. 2005;5:1437\u20131445.","DOI":"10.1111\/j.1600-6143.2005.00887.x"},{"key":"2019111704362880700_R25","doi-asserted-by":"crossref","unstructured":"Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714\u20131722.","DOI":"10.1053\/j.gastro.2003.09.033"},{"key":"2019111704362880700_R26","doi-asserted-by":"crossref","unstructured":"Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172\u2013180.","DOI":"10.1053\/gast.2000.8559"},{"key":"2019111704362880700_R27","doi-asserted-by":"crossref","unstructured":"Cortelezzi A, Vigano M, Zilioli VR, et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol. 2006;35:467\u2013469.","DOI":"10.1016\/j.jcv.2005.10.009"},{"key":"2019111704362880700_R28","doi-asserted-by":"crossref","unstructured":"Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37:625\u2013626.","DOI":"10.1038\/sj.bmt.1705290"},{"key":"2019111704362880700_R29","doi-asserted-by":"crossref","unstructured":"Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med. 2005;352:310\u2013311.","DOI":"10.1056\/NEJM200501203520324"},{"key":"2019111704362880700_R30","doi-asserted-by":"crossref","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673\u20132681.","DOI":"10.1056\/NEJMoa042957"},{"key":"2019111704362880700_R31","doi-asserted-by":"crossref","unstructured":"Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005;129:1198\u20131209.","DOI":"10.1053\/j.gastro.2005.06.055"},{"key":"2019111704362880700_R32","unstructured":"National Center for Disease Control and Prevention. Hepatitis C Fact Sheet. 1991. Accessed May 1, 2006."},{"key":"2019111704362880700_R33","doi-asserted-by":"crossref","unstructured":"Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1991;28:823\u2013830.","DOI":"10.1002\/hep.510280333"},{"key":"2019111704362880700_R34","doi-asserted-by":"crossref","unstructured":"Ribas A, Gale RP. Should people with hepatitis C virus infection receive a bone marrow transplant? Bone Marrow Transplant. 1997;19:97\u201399.","DOI":"10.1038\/sj.bmt.1700620"},{"key":"2019111704362880700_R35","doi-asserted-by":"crossref","unstructured":"Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423\u2013428.","DOI":"10.7326\/0003-4819-127-6-199709150-00002"},{"key":"2019111704362880700_R36","doi-asserted-by":"crossref","unstructured":"Kanamori H, Fukawa H, Maruta A, et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci. 1992;303:109\u2013111.","DOI":"10.1097\/00000441-199202000-00009"},{"key":"2019111704362880700_R37","unstructured":"Maruta A, Kanamori H, Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant. 1994;13:417\u2013422."},{"key":"2019111704362880700_R38","doi-asserted-by":"crossref","unstructured":"Zekri AR, Mohamed WS, Samra MA, Sherif GM, El Shehaby AM, El Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transpl Immunol. 2004;13:305\u2013311.","DOI":"10.1016\/j.trim.2004.10.001"},{"key":"2019111704362880700_R39","doi-asserted-by":"crossref","unstructured":"Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83:1224\u20131230.","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6"},{"key":"2019111704362880700_R40","doi-asserted-by":"crossref","unstructured":"Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol. 2003;25:184\u2013192.","DOI":"10.1097\/00043426-200303000-00002"},{"key":"2019111704362880700_R41","doi-asserted-by":"crossref","unstructured":"Peffault dL, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood. 2004;103:1618\u20131624.","DOI":"10.1182\/blood-2003-06-2145"},{"key":"2019111704362880700_R42","doi-asserted-by":"crossref","unstructured":"de Latour RP, Asselah T, Levy V, et al. Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 2005;36:709\u2013713.","DOI":"10.1038\/sj.bmt.1705120"},{"key":"2019111704362880700_R43","doi-asserted-by":"crossref","unstructured":"Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147\u20131171.","DOI":"10.1002\/hep.20119"},{"key":"2019111704362880700_R44","unstructured":"Strasser SI, McDonald GB. Hepatobiliary complications of hematopoietic stem cell transplantation. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff\u2019s Diseases of the Liver. Vol. 2. Philadelphia: Lippincott Williams & Wilkins; 2003:1635\u20131663."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/375\/1091690\/375_380ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/375\/1091690\/375_380ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T02:30:06Z","timestamp":1587263406000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/375\/19820\/Viral-Hepatitis-Manifestations-and-Management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.375","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}